French company Polyplus-transfection is about to launch a new reagent that has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.
The transfection reagent FectoVIR-AAV will be available from next month, and it is hoped that it will help to tackle the significant and well-identified bottleneck in manufacturing sufficient amounts of AAV viral vectors to treat patients.
"This will alleviate a major concern for the gene therapy sector"This manufacturing need will grow more intense as further gene therapies are commercialized, and reach late-stage clinical trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze